PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Author:
Affiliation:
1. Department of Obstetrics and Gynecology, Beijing Chao‐yang Hospital Capital Medical University Beijing China
Funder
Natural Science Foundation of Beijing Municipality
Publisher
Wiley
Subject
Cell Biology,Molecular Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.14133
Reference107 articles.
1. Cancer statistics, 2014
2. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
3. Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
4. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
5. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Cited by 116 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mechanism and rational combinations with GP‐2250, a novel oxathiazine derivative, in ovarian cancer;Cancer Medicine;2024-08
2. Dual-target EZH2 inhibitor: latest advances in medicinal chemistry;Future Medicinal Chemistry;2024-07-31
3. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29
4. Effects of PARP Inhibitors on Subsequent Platinum-Based Chemotherapy in Patients with Recurrent Ovarian Cancer;Cancers;2024-07-25
5. Nucleolar Localization of the RNA Helicase DDX21 Predicts Survival Outcomes in Gynecologic Cancers;Cancer Research Communications;2024-06-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3